Menu
ÚHKT

Impaktované publikace

[1]

Kayser, S.; Kramer M.; Martínez-Cuadrón, D.; Grenet, J.; Metzeler, K.H.; Sustkova, Z.; Luskin, M.R.; Brunner, A.M.; Elliott, M.A.; Gil, C.; Marini, S.C.; Ráčil, Z.; Cetkovsky, P.; et al.

Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study

[rok vydání 2022, impact factor 9.941 ]

[2]

Kayser, S.; Hills, R.K.; Langova, R.; Kramer, M.; Guijarro, F.; Sustkova, Z.; Estey, E.H.; Shaw, C.M.; Ráčil, Z.; Mayer, J.; Zak, P.; Baer, M.R.; Brunner, A.M.; Szotkowski, T.; Cetkovsky, P.; et al.

Characteristics and outcome of patients with acute myeloid leukaemia and t(8.16)(p11.p13): results from an International Collaborative Study*

[rok vydání 2021, impact factor 6.998 ]

[3]

Šálek, C.; Folber, F.; Froňková, E.; Pecherková, P.; Jelínková, H.; Hrabovský, Š.; Horáček, J.M.; Cetkovský, P.; Mayer, J.; Trka, J.; Doubek, M.

Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant

[rok vydání 2021, impact factor 6.998 ]

[4]

Šestáková, Š.; Cerovská, E.; Cyril Šálek, C.; Kundrát, D.; Ježíšková, I.; Folta, A.; Mayer, J.; Ráčil, Z.; Cetkovský, P.; Remešová, H.

A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel

[rok vydání 2022, impact factor 6.551 ]

[5]

Racil, Z.; Koritakova, E.; Sacha, T.; Klamova, H.; Belohlavkova, P.; Faber, E.; Rea, D.; Malaskova, L.; Prochazkova, J.; Zackova, D.; Voglova, J.; Waclaw, J.; Cetkovsky, P.; Zak, P.; Mayer, J.

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

[rok vydání 2018, impact factor 6.137 ]

[6]

Folta, A.; Culen, M.; Jeziskova, I.; Herudkova, Z.; Tom, N.; Hlubinkova, T.; Janeckova, V.; Durinikova, A.; Vydra, J.; Semerad, L.; Dvorakova, D.; Remesova, H.; Cerovska, E.; Cetkovsky, P.; et al.

Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients

[rok vydání 2019, impact factor 5.518 ]

[7]

Hubacek, P.; Maalouf, J.; Zajickova, M.; Kouba, M.; Cinek, O.; Hyncicova, K.; Fales, I.; Cetkovsky, P.

Failure of multiple antivirals to affect high HHV-6 DNAaemia resulting from viral chromosomal integration in case of severe aplastic anaemia

[rok vydání 2008, impact factor 5.516]

[8]

Morfin, F.; Dupuis-Girod, S.; Mundweiler, S.; Falcon, D.; Carrington, D.; Sedlacek, P.; Bierings, M.; Cetkovsky, P.; Kroes, A.C.; van Tol, M.J.; Thouvenot, D.:

In vitro susceptibility of adenovirus to antiviral drugs is species-dependent.

[rok vydání 2006, impact factor 5.286]

[9]

Weinbergerová, B.; Demel, I.; Víšek, B.; Válka, J.; Čerňan, M.; Jindra, P.; Novák, J.; Stejskal, L.; Kovácsová, F.; Kabut, T.; Szotkowski, T.; Hájek, R.; Žák, P.; Cetkovský, P.; Král, Z.; Mayer, J.

Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience

[rok vydání 2022, impact factor 5.271 ]

[10]

Hájková, H.; Fritz, M.H-Y.; Haškovec, C.; Schwarz, J.; Šálek, C.; Marková, J.; Krejčík, Z.; Dostálová Merkerová, M.; Kostečka, A.; Vostrý, M.; Fuchs, O.; Michalová, K.; Cetkovský, P.; Beneš, V.

CBFB - MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia

[rok vydání 2014, impact factor 4.812 ]

[11]

Racil, Z.; Buresova, L.; Brejcha, M.; Prochazkova, J.; Zounar, R.; Timilsina, S.; Razga, F.; Toskova, M.; Cetkovsky, P.; Mayer, J.

Clinical and laboratory features of leukemias at the time of diagnosis: an analysis of 1,004 consecutive patients.

[rok vydání 2011, impact factor 4.671 ]

[12]

Zackova, D.; Klamova, H.; Dusek, L.; Muzik, J.; Machova Polakova, K.; Moravcova, J.; Jurcek, T.; Dvorakova, D.; Racil, Z.; Pospisil, Z.; Oltova, A.; Michalova, K.; Brezinova, J.; Razga, F.; Doubek, M.; Cetkovsky, P.; Trneny, M.; Mayer, J.

Imatinib as the first line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

[rok vydání 2010, impact factor 4.671 ]

[13]

Hubacek, P.; Virgili, A.; Ward, K.N.; Pohlreich, D.; Keslova, P.; Goldova, B.; Markova, M.; Zajac, M.; Cinek, O.; Nacheva, E.P.; Sedlacek, P.; Cetkovsky, P.

HHV-6 DNA throughout the tissues of two stem cell transplant patients with chromosomally integrated HHV-6 and fatal CMV pneumonitis

[rok vydání 2009, impact factor 4.597]

[14]

Paterson, D.L.; David, K.; Mrsic, M.; Cetkovsky, P.; Weng, X.H.; Sterba, J.; Krivan, G.; Boskovic, D.; Lu, M.; Zhu, L.P.

Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC® : data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry

[rok vydání 2008, impact factor 4.328]

[15]

Morfin, F.; Dupuis-Girod, S.; Frobert, E.; Mundweiler, S.; Carrington, D.; Sedlacek, P.; Bierings, M.; Cetkovsky, P.; Kroes, A.C.M.; van Tol, M.J.D.; Thouvenot, D.

Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone

[rok vydání 2009, impact factor 4.322]

[16]

Semerad, L.; Sustkova, Z.; Cetkovsky, P.; Jindra, P.; Koristek, Z.; Novak, J.; Racil, Z.; Szotkowski, T.; Weinbergerova, B.; Zak, P.; Pospisil, Z.; Baranova, J.; Mayer, J.

The impact of centralised care of younger AML patients on treatment results: a retrospective analysis of real-world data from a national population-based registry

[rok vydání 2021, impact factor 4.089 ]

[17]

Sarova, I.; Brezinova, J.; Zemanova, Z.; Bystricka, D.; Krejcik, Z.; Soukup, P.; Cetkovsky, P.; Vydra, J.; Cermak, J.; Jonasova, A.; Michalova, K.

Characterization of chromosome 11 breakpoints and the areas of deletions and amplifications in newly diagnosed acute myeloid leukemia

[rok vydání 2012, impact factor 3.836 ]

[18]

Racil, Z.; Razga, F.; Buresova, L.; Jurcek, T.; Dvorakova, D.; Zackova, D.; Timilsina, S.; Cetkovsky, P.; Mayer, J.

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population

[rok vydání 2010, impact factor 3.576]

[19]

Racil, Z.; Klamova, H.; Voglova, J.; Faber, E.; Razga, F.; Zackova, D.; Buresova, L.; Cetkovsky, P.; Mayer, J.

Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

[rok vydání 2010, impact factor 3.576]

[20]

Šestáková, Š.; Krejčík, Z.; Folta, A.; Cerovská, E.; Šálek, C.; Dostálová Merkerová, M.; Pecherková, P.; Ráčil, Z.; Mayer, J.; Cetkovský, P.; Remešová, H.

DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations

[rok vydání 2019, impact factor 3.436 ]

Neimpaktované publikace

[1]

Cetkovský, P.

Fusarium

[rok vydání 2010]